Esteban Ribera Pascuet-rekin lankidetzan egindako argitalpenak (3)

2009

  1. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/ emtricitabine in HIV-1-infected patients with virological suppression

    Journal of Acquired Immune Deficiency Syndromes, Vol. 51, Núm. 3, pp. 290-297

  2. Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a lpv/r-containing haart: The atazip study

    Journal of Acquired Immune Deficiency Syndromes, Vol. 51, Núm. 1, pp. 29-36

2008

  1. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens

    HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313